title: Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study.
abstract: BACKGROUND
  Although cyclosporine has been found to be effective therapy for severe psoriasis, only limited data exist about efficacy and safety during long-term treatment with a low-dose regimen. Furthermore, little is known about the course of psoriasis after drug withdrawal.
  
  
  OBJECTIVE
  Our purpose was to assess the results of long-term therapy with cyclosporine for severe psoriasis with particular regard to efficacy and safety, as well as the disease course after stopping treatment.
  
  
  METHODS
  A multicenter study of 217 patients treated with 1.25, 2.5, or 5.0 mg/kg per day of cyclosporine was performed. Duration of treatment ranged from 6 to 30 months followed by a posttreatment period of 3 months. Efficacy was assessed by the Psoriasis Area and Severity Index and safety was monitored by clinical and laboratory investigations.
  
  
  RESULTS
  Patients with severe psoriasis showing a reduction in the Psoriasis Area and Severity Index of 75% with their individual dose of cyclosporine maintained clinical improvement during continuous maintenance therapy. Newly occurring side effects were less frequent during the maintenance phase than in the induction phase. After withdrawal of cyclosporine, worsening of psoriasis requiring antipsoriatic therapy was seen in about half of the patients.
  
  
  CONCLUSIONS
  Cyclosporine is effective for long-term therapy for severe psoriasis and does not lead to severe deterioration of the disease after drug withdrawal.
authors.affiliation: Department of Dermatology, University of Kiel, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Mrowietz
authors.forename: L
authors.initials: L
authors.lastname: Färber
authors.forename: H H
authors.initials: HH
authors.lastname: Henneicke-von Zepelin
authors.forename: H
authors.initials: H
authors.lastname: Bachmann
authors.forename: D
authors.initials: D
authors.lastname: Welzel
authors.forename: E
authors.initials: E
authors.lastname: Christophers
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D012449:Safety; D012459:Salicylates / Q000008:administration & dosage / Q000627:therapeutic use; D020156:Salicylic Acid; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D009824:Ointments; D012459:Salicylates; D014280:Triglycerides; D016572:Cyclosporine; D003404:Creatinine; D020156:Salicylic Acid